Expert Committee on Novel DPP-4 Inhibitor TRADJENTA (Linagliptin) in Treatment of Type 2 Diabetesmellitus

Diabetes Mellitus - Russian Federation
doi 10.14341/2072-0351-5527
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Endocrinology Research Centre

Related search

Emerging DPP-4 Inhibitors: Focus on Linagliptin for Type 2 Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2013English

DPP-4/SGLT2 Inhibitor Combined Therapy for Type 2 Diabetes

Prescriber
Pharmacology
2017English

Qtern: DPP-4 and SGLT2 Inhibitor Combination for Type 2 Diabetes

Prescriber
Pharmacology
2017English

Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)
2016English

Use of DPP-4 Inhibitors in Type 2 Diabetes: Focus on Sitagliptin

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2010English

DPP-4 Inhibitor and Alpha-Glucosidase Inhibitor Equally Improve Endothelial Function in Patients With Type 2 Diabetes: EDGE Study

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2014English

Need for Streamlined Use of DPP-4 Inhibitors in the Treatment of Type 2 Diabetes

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2016English

Linagliptin: Farmacology, Efficacy and Safety in Type 2 Diabetes Treatment

Diabetology and Metabolic Syndrome
Internal MedicineEndocrinologyMetabolismDiabetes
2013English

Anti-Angiogenic Effects of the DPP-4 Inhibitor Linagliptin via Inhibition of VEGFR Signalling in the Mouse Model of Oxygen-Induced Retinopathy

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy